While Merck's oral drug Molnupiravir has already been cleared by the United Kingdom to treat COVID-19, a Paraguayan laboratory has filed for its emergency registration in the South American ...

the pill developed by Merck. World tennis Number One and defending champion Novak Djokovic will not play the 2022 edition of the Australian Open in response to the vaccination requirement against ...

The green light means that Paxlovid – based on nirmatrelvir (formerly PF-07321332) and ritonavir – has been cleared for use in the US ahead of rival therapy molnupiravir from Merck & Co and ...

Merck already has a supply deal in place for molnupiravir with the US government, which has agreed a $1.2 billion order for 1.7 million doses at a price of $700 per course, as well as deals with ...

Merck reported adjusted earnings of $2.28 per share for second ... mainly Europe and Asia Pacific region. Lagevrio (molnupiravir) generated sales of $110 million in the second quarter, down 42% year ...

Merck reported adjusted earnings of $2.28 per ... mainly Europe and Asia Pacific region. Lagevrio (molnupiravir) generated sales of $110 million in the second quarter, down 42% year over year.

The federal regulator said it continues to receive data "as new information becomes available" from pharmaceutical company Merck on their drug molnupiravir, considered the first pill to ...

Merck has changed since its 2021 spin-off of women's health and biosimilar products in Organon. So far, some of the consequently lost revenues have been compensated by the pandemic-boosted sales of ...

The Committee for Medicinal Products for Human Use recommends marketing approval for Merck's Keytruda for treating two types of gynecologic cancers. The FDA approves MRK's Keytruda for first-line ...

LITESPARK-005 is part of Merck’s development program for Welireg comprised of four phase 3 trials in RCC, in which the company is evaluating Welireg in new combinations with other medicines ...

In 2021, the FDA blasted Merck for using a premature endpoint to pursue a Keytruda approval in early-stage triple-negative breast cancer (TNBC). Now, the PD-1 inhibitor has gold-standard overall ...

Merck & Co.’s best-selling drug Keytruda helped women with a hard-to-treat form of breast cancer live longer, according to the first study to show such a benefit in these patients. After five ...